Current approaches to the treatment of complicated pyelonephritis: protected cephalosporin use, including the combination of ceftriaxone/sulbactam

Main Article Content

Ya.A. Dombrovskyi
M.D. Ivanova


Infections of the urinary system occupy a leading place among nephrology pathology and infectious diseases in general, in particular, constitute a significant proportion of infections multiresistant microorganisms. The topic of this article is devoted to the etiology and the key stages of the pathogenesis of infectious lesions of the urinary system, particularly complicated pyelonephritis, as well as the comparative characteristics of drugs used in the treatment of these patients. The main part of the article is an analysis of pharmacodynamics, efficacy, safety and expediency of the combined antimicrobial drug ceftriaxone/sulbactam.

Article Details

How to Cite
Dombrovskyi, Y., and M. Ivanova. “Current Approaches to the Treatment of Complicated Pyelonephritis: Protected Cephalosporin Use, Including the Combination of ceftriaxone/Sulbactam”. KIDNEYS, no. 1.11, Feb. 2015, pp. 7-11, doi:10.22141/2307-1257.
Guest Articles


Stamm W.E. Scientific and clinical challenges in the management of urinary tract infections // Am. J. Med. 2002; 113 (1A): 1S-4S.

Пиріг Л.А., Іванов Д.Д. та ін. Нефрологія: національний підручник. — Донецьк: Видавець Заславський О.Ю., 2014. — С. 80-104.

Grabe M., Bjerklund-Johansen T.E. et al. Guidelines on Urologiсal Infections. European Association of Urology, 2013.

Schappert S.M. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997 // Vital Health Stat. 13. 1999; 143: 1-39.

Wang S., Shi Y.K., Huang X.B., Ma K., Xu Q.Q., Xiong L.L., Li J.X., Wang X.F. Bacterial culture and drug sensitivity analysis of upper urinary tract calculi complicating with infection // Beijing Da Xue Xue Bao. 2014 Oct 18; 46 (5): 798-801.

Poudyal N., Gyawali N., Gurung R., Bhattarai N.R., Baral R., Khanal B., Shrestha S., Amatya R., Bhattacharya S.K. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli // Nepal Med. Coll. J. 2012 Mar; 14(1): 5-8.

Xin X., Jian L., Xia X., Jia B., Huang W. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections // Ann. Clin. Microbiol. Antimicrob. 2013 Dec 9; 12: 38. doi: 10.1186/1476-0711-12-38.

Rit K., Naha A. In vitro microbial efficacy of sulbactomax: A novel fixed dose combination of ceftriaxone, sulbactum, and ethylenediaminetetraacetic acid against metallo β-lactamases producing strains of non-fermenters // CHRISMED J. Health Res. 2014; 1: 210-1.

Payasi A., Chaudhary M., Gupta A., Dwivedi V.K., Bhatnagar A. Pharmacokinetic study of sulbactomax // J. Toxicol. Sci. 2010 Aug; 35(4): 459-64.

Shrivastava S.M., Singh R., Tariq A., Siddiqui M.R., Yadav J., Negi P.S., Chaudhary M. A novel high performance liquid chromatographic method for simultaneous determination of ceftriaxone and sulbactam in sulbactomax // Int. J. Biomed. Sci. 2009 Mar; 5(1): 37-43.

Peco-Antić A., Paripović D., Buljugić S., Spasojević-Dimitrijeva B., Cvetković M., Laban-Nestorović S., Milosevski-Lomić G. In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis // Srp. Arh. Celok. Lek. 2012 May-Jun; 140 (5–6): 321-5.

Іванов Д.Д., Кушніренко С.В. Клінічний досвід застосування сульбактомаксу при пієлонефриті в дітей // Новини медицини та фармації. — 2010. — 5 (311).

Winberg J., Bergstron T., Jacobsson B. Morbidity, age and sex distribution: recurrences and renal scarring in symptomatic urinary tract infection in childhood // Kidney Int. 1975; 3 (suppl.): S101-S106.

Foxman B., Barlow R., d’Arcy H. et al. Urinary tract infection: estimated incidence and associated costs // Ann. Epidemiol. 2000; 10: 509-515.

Kunin C.M. Urinary tract infections in females // Clin. Infect. Dis. 1994; 18: 1-12.

Karlowsky J.A., Kelly L.J., Thornsberry C., Jones M.E., Sahm D.F. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States // Antimicrob. Agents Chemother. 2002 Aug; 46(8): 2540-5.

Karlowsky J.A., Thornsberry C., Jones M.E., Sahm D.F. Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin // Clin. Infect. Dis. 2003 Jan 15; 36(2): 183-7.

Gonzalez C.M., Schaeffer A.J. Treatment of urinary tract infection: what’s old, what’s new, and what works // World J. Urol. 1999; 17: 372-382.

Nickel J.K. Management of urinary tract infections: historical perspective and current strategies: part 2 — modern management // J. Urol. 2005; 173: 27-32.

Scholes D., Hooton T.M., Roberts D.L. et al. Risk factors for recurrent urinary tract infection in young women // J. Infect. Dis. 2000; 182: 1177-1182.

Kahlmeter G. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study // Int. J. Antimicrob. Agents. 2003 Oct; 22 Suppl. 2: 49-52.

Most read articles by the same author(s)

1 2 3 > >>